Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

Christian W. Eskelund, Christina Dahl, Jakob W. Hansen, Maj Westman, Arne Kolstad, Lone B. Pedersen, Carmen P. Montano-Almendras, Simon Husby, Catja Freiburghaus, Sara Ek, Anja Pedersen, Carsten Niemann, Riikka Räty, Peter Brown, Christian H. Geisler, Mette K. Andersen, Per Guldberg, Mats Jerkeman, Kirsten Grønbæk

Blood (2017) 130 (17): 1903–1910.

https://doi.org/10.1182/blood-2017-04-779736

Published: 2017

Includes: Supplemental data

Journal Articles

Targeted Sequencing of Diagnostic Samples Correlated to Clinical Outcome: Data from the Nordic Mantle Cell Lymphoma (MCL2 and MCL3) Studies with Long-Term Follow-up

Christian Winther Eskelund, Jakob W Hansen, Maj Karoline Westman, MSc, Catja Freiburghaus, PhD, Sara Ek, PhD, Lone B Pedersen, Mette K Andersen, Riikka Räty, Arne Kolstad, Mats Jerkeman, Peter de Nully Brown, MD PhD, Christian H Geisler, Kirsten Groenbaek

Blood (2016) 128 (22): 1095.

https://doi.org/10.1182/blood.V128.22.1095.1095

Published: 2016

Journal Articles

Molecular Characterization Of De Novo and Therapy-Related MDS/AML With Der(1;7)(q10;p10)

Westman K Maj, MSc, Mette K. Andersen, MD, PhD

Blood (2013) 122 (21): 2585.

https://doi.org/10.1182/blood.V122.21.2585.2585

Published: 2013

Journal Articles

Cryopreserved ovarian cortex from patients with leukemia in complete remission contains no apparent viable malignant cells

Tine Greve, Erik Clasen-Linde, Morten T. Andersen, Mette K. Andersen, Stine D. Sørensen, Mikkel Rosendahl, Elisabeth Ralfkiær, Claus Yding Andersen

Blood (2012) 120 (22): 4311–4316.

https://doi.org/10.1182/blood-2012-01-403022

Published: 2012

Includes: Supplemental data

Journal Articles

Allelic Methylation Levels of VTRNA2-1 Predict Outcome in Higher Risk MDS Patients Not Treated by Azacytidine.

Marianne B. Treppendahl, MD, Magnus Tobiasson, MD, Anni Aggerholm, PhD, Mohsen Karimi, PhD, Trine Silkjaer, MD, Lone S. Friis, MD, PhD, Mette K. Andersen, PhD, Lars Kjeldsen, MD, PhD, Mette S. Holm, MD, PhD, Eva Hellström-Lindberg, PhD, Kirsten Grønbæk, MD, DMSc

Blood (2012) 120 (21): 2394.

https://doi.org/10.1182/blood.V120.21.2394.2394

Published: 2012

Journal Articles

High Early Death Rate with Excellent Survival Beyond Day 30 in Acute Promyelocytic Leukemia Confirmed in Unselected Patients: Results of a Population-Based Registry Study

Jan M. Norgaard, MD, PhD, Lene Sofie Granfeldt Ostgard, MD, Eigil Kjeldsen, MD, Mette S. Holm, MD, PhD, Lars Kjeldsen, MD, PhD, Maria Kallenbach, MD, Marianne T. Severinsen, MD, PhD, Preben Johansen, MD, Lone S. Friis, MD, PhD, Duruta Weber, MD, PhD, Gitte Kerndrup, Birgitte Preiss, MD, Morten K. Jensen, MD, Inge H. Dufva, MD, Susanne Timshel, MD, Mette K. Andersen, MD, PhD, Ove J. Nielsen, MD, PhD

Blood (2012) 120 (21): 3542.

https://doi.org/10.1182/blood.V120.21.3542.3542

Published: 2012

Journal Articles

Different Cytogenetic Patterns in Specified Categories of Secondary AML: Results of a Population-Based Registry Study,

Jan M. Norgaard, MD, PhD, Lene S.G. Oestgaard, MD, Mette K. Andersen, MD, PhD, Maria Kallenbach, MD, Preben Johansen, MD, Knud Bendix, MD, PhD, Gitte Kerndrup, MD, PhD, Birgitte Preiss, MD, Inge Dufva, MD, Susanne Timshel, MD, Joergen Kristensen, MD, PhD, Peter de Nully Brown

Blood (2011) 118 (21): 3586.

https://doi.org/10.1182/blood.V118.21.3586.3586

Published: 2011

Journal Articles

IDH1 and IDH2 Mutations in Therapy-Related Acute Myeloid Leukemia Are Associated with a Normal Karyotype or Der(1;7)(q10;p10) Combined with RUNX1 Mutations,

Maj K. Westman, Morten T. Andersen, Jens Pedersen-Bjergaard, MD, PhD, Mette K. Andersen, MD, PhD

Blood (2011) 118 (21): 3514.

https://doi.org/10.1182/blood.V118.21.3514.3514

Published: 2011

Journal Articles

Epigenetic Silencing of a Novel Candidate Tumor Suppressor “miR” Predicts Poor Prognosis In High-Risk MDS and AML.

Marianne B. Treppendahl, MD, Xiangning Qiu, MD, Christoffer Hother, MD, Mette K. Andersen, MD, PhD, Lars Kjeldsen, MD, PhD, Peter Jones, Professor, Gangning Liang, PhD, Kirsten Gr∅nbæk, MD, PhD

Blood (2010) 116 (21): 3629.

https://doi.org/10.1182/blood.V116.21.3629.3629

Published: 2010

Journal Articles

Relapsed Childhood High Hyperdiploid Acute Lymphoblastic Leukemia: Genome-Wide Screening Reveals the Presence of Preleukemic Ancestral Clones and the Secondary Nature of Microdeletions and RTK-RAS Mutations.

Josef Davidsson, PhD, Kajsa Paulsson, PhD, David Lindgren, PhD, Henrik Lilljebjörn, MS, Tracy Chaplin, MS, Erik Forestier, MD, PhD, Mette K Andersen, MD, PhD, Ann Nordgren, MD, PhD, Richard Rosenquist, MD, PhD, Thoas Fioretos, MD, PhD, Bryan D Young, PhD, Bertil Johansson, MD, PhD

Blood (2009) 114 (22): 2591.

https://doi.org/10.1182/blood.V114.22.2591.2591

Published: 2009

Journal Articles

New Prognostic Data on Rare Cytogenetic Abnormalities in MDS: A Collaborative Study of the International Working Group on MDS Cytogenetics

Julie Schanz, Marilyn L. Slovak, Kazuma Ohyashiki, Francesc Solé, Maria del Mar Mallo, Christian Steidl, Michael Pfeilstoecker, Thomas Noesslinger, Barbara Hildebrandt, Michael Luebbert, Mette K Andersen, Aristoteles Giagounidis, Peter Valent, Christa Fonatsch, Ulrich Germing, Detlef Haase

Blood (2008) 112 (11): 2688.

https://doi.org/10.1182/blood.V112.11.2688.2688

Published: 2008

Journal Articles

CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia

Pär Josefsson, Christian H. Geisler, Henrik Leffers, Jørgen H. Petersen, Mette K. Andersen, Jesper Jurlander, Anne Mette Buhl

Blood (2007) 109 (11): 4973–4979.

https://doi.org/10.1182/blood-2006-11-054916

Published: 2007

Journal Articles

Validation of the Prognostic Significance of the Disease Specific Gene CLLU1 in Chronic Lymphocytic Leukemia.

Par Josefsson, MD, Jesper Jurlander, MD, PhD, Christian H. Geisler, MDD.MS, Lone B. Pedersen, Lone Bach, Mette K. Andersen, MD, Henrik Leffers, MS, Anne Mette Buhl, PhD

Blood (2005) 106 (11): 709.

https://doi.org/10.1182/blood.V106.11.709.709

Published: 2005

Journal Articles

Genetic Pathways in t-MDS and t-AML, a Revised Model.

Jens Pedersen-Bjergaard, MD, Ph.D, Debes H. Christiansen, MS, Mette K. Andersen, MD

Blood (2004) 104 (11): 2993.

https://doi.org/10.1182/blood.V104.11.2993.2993

Published: 2004

Journal Articles

Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation

Debes H. Christiansen, Mette K. Andersen, Jens Pedersen-Bjergaard

Blood (2004) 104 (5): 1474–1481.

https://doi.org/10.1182/blood-2004-02-0754

Published: 2004

Journal Articles

Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia

Jens Pedersen-Bjergaard, Mette K. Andersen, Debes H. Christiansen, Claus Nerlov

Blood (2002) 99 (6): 1909–1912.

https://doi.org/10.1182/blood.V99.6.1909

Published: 2002

NARROW

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

Targeted Sequencing of Diagnostic Samples Correlated to Clinical Outcome: Data from the Nordic Mantle Cell Lymphoma (MCL2 and MCL3) Studies with Long-Term Follow-up

Molecular Characterization Of De Novo and Therapy-Related MDS/AML With Der(1;7)(q10;p10)

Cryopreserved ovarian cortex from patients with leukemia in complete remission contains no apparent viable malignant cells

Allelic Methylation Levels of VTRNA2-1 Predict Outcome in Higher Risk MDS Patients Not Treated by Azacytidine.

High Early Death Rate with Excellent Survival Beyond Day 30 in Acute Promyelocytic Leukemia Confirmed in Unselected Patients: Results of a Population-Based Registry Study

Different Cytogenetic Patterns in Specified Categories of Secondary AML: Results of a Population-Based Registry Study,

IDH1 and IDH2 Mutations in Therapy-Related Acute Myeloid Leukemia Are Associated with a Normal Karyotype or Der(1;7)(q10;p10) Combined with RUNX1 Mutations,

Epigenetic Silencing of a Novel Candidate Tumor Suppressor “miR” Predicts Poor Prognosis In High-Risk MDS and AML.

Relapsed Childhood High Hyperdiploid Acute Lymphoblastic Leukemia: Genome-Wide Screening Reveals the Presence of Preleukemic Ancestral Clones and the Secondary Nature of Microdeletions and RTK-RAS Mutations.

New Prognostic Data on Rare Cytogenetic Abnormalities in MDS: A Collaborative Study of the International Working Group on MDS Cytogenetics

CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia

Validation of the Prognostic Significance of the Disease Specific Gene CLLU1 in Chronic Lymphocytic Leukemia.

Genetic Pathways in t-MDS and t-AML, a Revised Model.

Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation

Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only